| scholarly article | Q13442814 |
| P50 | author | Daniel C. Liebler | Q37839189 |
| M Li | Q80533029 | ||
| P2093 | author name string | Hye-Jung Kim | |
| Hyoung-Joo Lee | |||
| De Lin | |||
| P2860 | cites work | Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. | Q36140332 |
| Quantitative analysis of energy metabolic pathways in MCF-7 breast cancer cells by selected reaction monitoring assay | Q36144177 | ||
| Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum | Q36280125 | ||
| Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer. | Q36455720 | ||
| Proteome-wide selected reaction monitoring assays for the human pathogen Streptococcus pyogenes | Q36503352 | ||
| Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma | Q37294438 | ||
| Phosphotyrosine profiling of NSCLC cells in response to EGF and HGF reveals network specific mediators of invasion. | Q38257674 | ||
| Proteogenomic analysis reveals unanticipated adaptations of colorectal tumor cells to deficiencies in DNA mismatch repair. | Q39061655 | ||
| Proteomic consequences of a single gene mutation in a colorectal cancer model | Q39439499 | ||
| Mutant and Wild-type Ras: Co-conspirators in Cancer | Q41889427 | ||
| Selectivity of LC-MS/MS analysis: implication for proteomics experiments. | Q43864979 | ||
| Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib | Q46618741 | ||
| Isotope dilution--mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I | Q64134355 | ||
| Molecular Genetics of Colorectal Cancer | Q82521439 | ||
| KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib | Q21563446 | ||
| The protein kinase complement of the human genome | Q24324497 | ||
| Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer | Q24563539 | ||
| Cell signaling by receptor tyrosine kinases | Q24598357 | ||
| Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks | Q24633890 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| The protein tyrosine kinase family of the human genome | Q28140214 | ||
| Protein tyrosine kinase structure and function | Q28145008 | ||
| Oncogenic kinase signalling | Q28189493 | ||
| Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules | Q28256069 | ||
| Targeting cancer with small molecule kinase inhibitors | Q29547395 | ||
| Differential analysis of gene regulation at transcript resolution with RNA-seq | Q29614490 | ||
| Skyline: an open source document editor for creating and analyzing targeted proteomics experiments | Q30080030 | ||
| RNA-seq data analysis at the gene and CDS levels provides a comprehensive view of transcriptome responses induced by 4-hydroxynonenal | Q30668800 | ||
| Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases | Q32062433 | ||
| Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib | Q33161299 | ||
| Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry | Q33621574 | ||
| Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics | Q33674206 | ||
| Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma | Q33794491 | ||
| Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels | Q33850627 | ||
| Evaluating melanoma drug response and therapeutic escape with quantitative proteomics | Q33850665 | ||
| Protein Expression Signatures for Inhibition of Epidermal Growth Factor Receptor-mediated Signaling | Q34093266 | ||
| Parallel Reaction Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted Proteomics | Q34292436 | ||
| Targeted quantitation of proteins by mass spectrometry. | Q34630866 | ||
| Methods for Peptide and Protein Quantitation by Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry | Q35026899 | ||
| Phosphotyrosine signaling analysis in human tumors is confounded by systemic ischemia-driven artifacts and intra-specimen heterogeneity | Q35251771 | ||
| Large-Scale Targeted Proteomics Using Internal Standard Triggered-Parallel Reaction Monitoring (IS-PRM). | Q35692132 | ||
| Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks | Q35749545 | ||
| Precision of multiple reaction monitoring mass spectrometry analysis of formalin-fixed, paraffin-embedded tissue | Q36011667 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 682-691 | |
| P577 | publication date | 2015-12-02 | |
| P1433 | published in | Molecular & Cellular Proteomics | Q6895932 |
| P1476 | title | Quantitative Profiling of Protein Tyrosine Kinases in Human Cancer Cell Lines by Multiplexed Parallel Reaction Monitoring Assays | |
| P478 | volume | 15 |
| Q37651691 | A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research. |
| Q28066912 | Advances in targeted proteomics and applications to biomedical research |
| Q49922966 | Application of targeted mass spectrometry in bottom-up proteomics for systems biology research. |
| Q47374639 | Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. |
| Q37619708 | Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples. |
| Q39714786 | Efficient Microscale Basic Reverse Phase Peptide Fractionation for Global and Targeted Proteomics |
| Q39175714 | Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer |
| Q26775066 | Parallel Reaction Monitoring: A Targeted Experiment Performed Using High Resolution and High Mass Accuracy Mass Spectrometry |
| Q39374028 | Protein turnover measurement using selected reaction monitoring-mass spectrometry (SRM-MS). |
| Q36382143 | Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma |
| Q47285459 | Selected reaction monitoring approach for validating peptide biomarkers |
| Q53078264 | Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor. |
| Q90315291 | The whole-genome landscape of Burkitt lymphoma subtypes |
| Q64968529 | To reveal pharmacological targets and molecular mechanisms of curcumol against interstitial cystitis. |
Search more.